Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(33.3%)
Phase 2
1(33.3%)
Phase 3
1(33.3%)
3Total
Phase 1(1)
Phase 2(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05060705Phase 2Not Yet Recruiting

"Efesovir" (FS-1) for COVID-19, Phase 2

Role: lead

NCT02607449Phase 3Completed

FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis

Role: lead

NCT04174937Phase 1Completed

PA Tolerability, Safety and Pharmacokinetics in Healthy Volunteers

Role: lead

All 3 trials loaded